Iterum Operating Income from 2010 to 2026
| ITRM Stock | USD 0.27 0.03 12.50% |
Operating Income | First Reported 2016-12-31 | Previous Quarter -5.5 M | Current Value -7.4 M | Quarterly Volatility 7.3 M |
Check Iterum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iterum Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 493 K, Interest Income of 1 M or Depreciation And Amortization of 242.8 K, as well as many indicators such as Price To Sales Ratio of 1.8 K, Dividend Yield of 0.0 or Days Sales Outstanding of 10.4 K. Iterum financial statements analysis is a perfect complement when working with Iterum Therapeutics Valuation or Volatility modules.
Iterum | Operating Income | Build AI portfolio with Iterum Stock |
Evaluating Iterum Therapeutics's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Iterum Therapeutics PLC's fundamental strength.
Latest Iterum Therapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Iterum Therapeutics PLC over the last few years. Operating Income is the amount of profit realized from Iterum Therapeutics PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Iterum Therapeutics PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Iterum Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iterum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Iterum Operating Income Regression Statistics
| Arithmetic Mean | (29,343,166) | |
| Coefficient Of Variation | (84.69) | |
| Mean Deviation | 16,700,353 | |
| Median | (21,500,400) | |
| Standard Deviation | 24,850,777 | |
| Sample Variance | 617.6T | |
| Range | 88.7M | |
| R-Value | (0.27) | |
| Mean Square Error | 610.2T | |
| R-Squared | 0.07 | |
| Significance | 0.29 | |
| Slope | (1,335,829) | |
| Total Sum of Squares | 9881T |
Iterum Operating Income History
Other Fundumenentals of Iterum Therapeutics PLC
Iterum Therapeutics Operating Income component correlations
Click cells to compare fundamentals
About Iterum Therapeutics Financial Statements
Iterum Therapeutics investors utilize fundamental indicators, such as Operating Income, to predict how Iterum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -21.5 M | -22.6 M | |
| Non Operating Income Net Other | 176.4 K | 156.8 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Iterum Therapeutics Correlation against competitors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Pharmaceuticals sector continue expanding? Could Iterum diversify its offerings? Factors like these will boost the valuation of Iterum Therapeutics. Market participants price Iterum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iterum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.72) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Iterum Therapeutics PLC requires distinguishing between market price and book value, where the latter reflects Iterum's accounting equity. The concept of intrinsic value - what Iterum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Iterum Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iterum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.